Skip to main content

Navigation group

Type at least 3 characters
1,081 articles

Articles

Original Research

Published on 23 Aug 2021

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

in Multiple Sclerosis and Neuroimmunology

  • Marina Boziki
  • Christos Bakirtzis
  • Virginia Giantzi
  • Styliani-Aggeliki Sintila
  • Stylianos Kallivoulos
  • Theodora Afrantou
  • Ioannis Nikolaidis
  • Panagiotis Ioannidis
  • Theodoros Karapanayiotides
  • Ioanna Koutroulou
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
Frontiers in Neurology
doi 10.3389/fneur.2021.699844
  • 4,056 views
  • 9 citations

Original Research

Published on 16 Aug 2021

Monoacylglycerol Lipase Inhibitor MJN110 Reduces Neuronal Hyperexcitability, Restores Dendritic Arborization Complexity, and Regulates Reward-Related Behavior in Presence of HIV-1 Tat

in Multiple Sclerosis and Neuroimmunology

  • Alexis F. League
  • Benjamin L. Gorman
  • Douglas J. Hermes
  • Clare T. Johnson
  • Ian R. Jacobs
  • Barkha J. Yadav-Samudrala
  • Justin L. Poklis
  • Micah J. Niphakis
  • Benjamin F. Cravatt
  • Aron H. Lichtman
Monoacylglycerol Lipase Inhibitor MJN110 Reduces Neuronal Hyperexcitability, Restores Dendritic Arborization Complexity, and Regulates Reward-Related Behavior in Presence of HIV-1 Tat
Frontiers in Neurology
doi 10.3389/fneur.2021.651272
  • 4,431 views
  • 14 citations